Phase II Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older

A Randomized, Double-blind, Dose-exploring, Placebo-controlled, Multi-center Phase II Clinical Trial Evaluating the Safety and Immunogenicity of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older

To evaluate the safety and immunogenicity of COVID-19 mRNA vaccine in people aged 18 years and older, 300 participants will be enrolled and divided into two groups: low- and high-dose groups. Each dose group (150 people) will be divided into 2 age groups (75 each):18 to 59 years old and ≥ 60 years old. The subjects will be randomized into vaccine group or placebo group in a ratio of 2:1. Subjects will complete 2 doses of vaccination on Day 0 and Day 21, in which the low-dose group will received 0.3 ml of the study vaccine or placebo, and the high dose group received 0.5 ml of the study vaccine or placebo.

Study Overview

• Status: Completed
• Conditions: COVID-19
• Intervention / Treatment: Biological: COVID-19 mRNA vaccine; Biological: Placebo

• Study Type: Interventional
• Enrollment (Actual): 150
• Phase: Phase 2

Contacts and Locations

Study Locations

• China
  • Beijing
    • Beijing, Beijing, China
      • Beijing Friendship Hospital
  • Hebei
    • Langfang, Hebei, China
      • Hebei Petro China Center Hospital
  • Hunan
    • Changsha, Hunan, China
      • Hunan Provincial Center for Disease Control and Prevention

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Adults aged 18 years and above with BMI not lower than 18 ;
2. Volunteers are able and willing to comply with the requirements of the clinical trial protocol, and volunteers or witnesses can sign informed consent forms;
3. Willing to discuss the medical history with the investigator or doctor and allow access to all medical records related to this trial;
4. Provide 48-hour PCR negative report;
5. Have not received any other COVID-19 vaccines.

Exclusion Criteria:

• Criteria for exclusion of the first dose

  1. Other medical or psychiatric conditions, including recent (within the past year) or current presence of suicidal ideation/behavior, or laboratory abnormalities that may increase the risk of participating in the study, or subjects who are not suitable to participate in the study according to the investigator's judgment;
  2. Positive for human immunodeficiency virus (HIV);
  3. History of infection or disease history of Middle East Respiratory Syndrome (MERS), SARS or other coronaviruses or related immunizations;
  4. History of serious adverse reactions associated with the vaccine and/or a history of severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine under study;
  5. Immunocompromised patients with known or suspected immunodeficiency identified by medical history and/or physical examination;
  6. Bleeding constitution or condition associated with prolonged bleeding which investigators believe that intramuscular injection is contraindicated;
  7. Women who test positive for blood pregnancy or are breastfeeding, volunteers or their partners have a pregnancy plan within 12 months;
  8. Severe hypertension and uncontrollable medication (on-site measurement: systolic blood pressure ≥ 160mmHg, diastolic blood pressure ≥ 100mmHg);
  9. Have a serious chronic disease or the condition is in the progression period can not be smoothly controlled, such as diabetes, thyroid disease, etc.;
  10. History of severe myocarditis, pericarditis and other heart diseases;
  11. Plans to receive other vaccines within 28 days before and after receiving the test vaccine;
  12. Those receiving immunosuppressive therapy, including cytotoxic drugs or systemic corticosteroids, such as for cancer or autoimmune diseases, or who were scheduled to receive treatment throughout the study period. If systemic corticosteroids are used in a short period of time (< 14 days) for the treatment of acute illness, subjects should not enter this study until at least 28 days after corticosteroid therapy has been discontinued prior to study vaccination. Inhalation/spraying, intra-articular, intraskeletal, or topical (skin or eyes) use of corticosteroids is permitted;
  13. Receiving blood/plasma products or immunoglobulins 60 days prior to study vaccination or plan to receive for the entire study duration;
  14. Engage in other interventional studies within 28 days prior to entering the study and/or during the study's participation;
  15. Participated in other interventional studies of lipid-containing nanoparticles;
  16. Have symptoms of COVID-19 such as respiratory symptoms, fever, cough, shortness of breath, and dyspnea;
  17. Fever, axillary temperature > 37.0 °C.

Second dose exclusion criteria:

1. Severe allergic reactions occur after the first vaccination;
2. Serious adverse reactions with causal relationship during the first vaccination;
3. Those who are newly discovered or newly occurring after the first vaccination do not meet the inclusion criteria of the first dose or meet the exclusion criteria of the first dose, and the investigator shall decide whether to continue to participate in the study;
4. Other reasons for exclusion that the investigators believe.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

8

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Vaccine Group, low dose, 18-59 year-old; 2 doses of COVID-19 mRNA vaccine (30µg, 0.3 ml) on Day 0 and Day 21	Biological: COVID-19 mRNA vaccine; 2 doses of vaccine on Day 0 and Day 21
Experimental: Vaccine Group, low dose, 60 year-old and above; 2 doses of COVID-19 mRNA vaccine (30µg, 0.3 ml) on Day 0 and Day 21	Biological: COVID-19 mRNA vaccine; 2 doses of vaccine on Day 0 and Day 21
Experimental: Vaccine Group, high dose, 18-59 year-old; 2 doses of COVID-19 mRNA vaccine (50µg, 0.5 ml) on Day 0 and Day 21	Biological: COVID-19 mRNA vaccine; 2 doses of vaccine on Day 0 and Day 21
Experimental: Vaccine Group, high dose, 60 year-old and above; 2 doses of COVID-19 mRNA vaccine (50µg, 0.5 ml) on Day 0 and Day 21	Biological: COVID-19 mRNA vaccine; 2 doses of vaccine on Day 0 and Day 21
Placebo Comparator: Placebo Group, low dose, 18-59 year-old; 2 doses of placebo (0µg, 0.3 ml) on Day 0 and Day 21	Biological: Placebo; 2 doses of placebo on Day 0 and Day 21
Placebo Comparator: Placebo Group, low dose, 60 year-old and above; 2 doses of placebo (0µg, 0.3 ml) on Day 0 and Day 21	Biological: Placebo; 2 doses of placebo on Day 0 and Day 21
Placebo Comparator: Placebo Group, high dose, 18-59 year-old; 2 doses of placebo (0µg, 0.5 ml) on Day 0 and Day 21	Biological: Placebo; 2 doses of placebo on Day 0 and Day 21
Placebo Comparator: Placebo Group, high dose, 60 year-old and above; 2 doses of placebo (0µg, 0.5 ml) on Day 0 and Day 21	Biological: Placebo; 2 doses of placebo on Day 0 and Day 21

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Immunogenicity of wild type neutralizing antibodies	GMT of wild type neutralizing antibodies	28 days after complete immunization
Immunogenicity of wild type neutralizing antibodies	Sero-conversation rate of wild type neutralizing antibodies	28 days after complete immunization
The incidence of adverse reactions (AR)	To evaluate the incidence of adverse reactions (AR) in all subjects	Within 14 days of each vaccination

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The incidence of adverse reactions (AR)	To evaluate the incidence of adverse reactions (AR) in all subjects	Within 28 days of complete immunization
The incidence of adverse reactions (AR)	To evaluate the incidence of adverse reactions (AR) in all subjects	Within 60 minutes of each vaccination
The incidence of SAE, MAE and AESI	To evaluation the incidence of SAE, MAE, and AESI in all subjects	12 months after complete vaccination
Immunogenicity of wild type neutralizing antibodies	Sero-conversation rate of wild type neutralizing antibodies	Before the 1st dose, 14 days after the 2nd dose, and 3, 6, 12 months after the 2nd dose
Immunogenicity of wild type neutralizing antibodies	GMT of wild type neutralizing antibodies	Before the 1st dose, 14 days after the 2nd dose, and 3, 6, 12 months after the 2nd dose
Immunogenicity of wild type neutralizing antibodies	GMI of wild type neutralizing antibodies	Before the 1st dose, 14 days after the 2nd dose, and 3, 6, 12 months after the 2nd dose
Immunogenicity of wild type neutralizing antibodies	GMI of wild type neutralizing antibodies	28 days after complete immunization
Immunogenicity of anti-S-RBD Ig G antibodies	Sero-conversation rate of anti-S-RBD Ig G antibodies	Before the 1st dose, 14 days after the 2nd dose, 28 days after the 2nd dose and month 3,6,12 months after 2nd vaccination
Immunogenicity of anti-S-RBD Ig G antibodies	GMC of anti-S-RBD Ig G antibodies	before the 1st dose, 14 days after the 2nd dose, 28 days after the 2nd dose and month 3,6,12 months after 2nd vaccination
Immunogenicity of anti-S-RBD Ig G antibodies	GMI of anti-S-RBD Ig G antibodies	before the 1st dose, 14 days after the 2nd dose, 28 days after the 2nd dose and month 3,6,12 months after 2nd vaccination
Cellular immunity	The response levels and positive rates of IL-2 produced by S protein RBD by ICS in the first 15 subjects in each group	Before the 1st dose, 14 days after the 2nd dose, 28 days after the 2nd dose and month 3,6,12 months after 2nd vaccination
Cellular immunity	The response levels and positive rates of IL-4 produced by S protein RBD by ICS in the first 15 subjects in each group	Before the 1st dose, 14 days after the 2nd dose, 28 days after the 2nd dose and month 3,6,12 months after 2nd vaccination
Cellular immunity	The response levels and positive rates of IL-5 produced by S protein RBD by ICS in the first 15 subjects in each group	Before the 1st dose, 14 days after the 2nd dose, 28 days after the 2nd dose and month 3,6,12 months after 2nd vaccination
Cellular immunity	The response levels and positive rates of IL-17 produced by S protein RBD by ICS in the first 15 subjects in each group	Before the 1st dose, 14 days after the 2nd dose, 28 days after the 2nd dose and month 3,6,12 months after 2nd vaccination
Cellular immunity	The response levels and positive rates of IFN-γ produced by S protein RBD by ICS in the first 15 subjects in each group	Before the 1st dose, 14 days after the 2nd dose, 28 days after the 2nd dose and month 3,6,12 months after 2nd vaccination
Changes in laboratory indicators	Changes in white blood cell count	Before 1st dose and 28 days after second dose
Changes in laboratory indicators	Changes in neutrophils	Before 1st dose and 28 days after second dose
Changes in laboratory indicators	Changes in lymphocyte count	Before 1st dose and 28 days after second dose
Changes in laboratory indicators	Changes in platelet count	Before 1st dose and 28 days after second dose
VOC/VOI serum cross neutralization	To evaluated the level of VOC/VOI serum cross neutralization results in all subjects.	28 days after complete immunization

Collaborators and Investigators

• Sponsor: CanSino Biologics Inc.
• Investigators: Principal Investigator: Tao Huang, Hunan Provincial Center for Disease Control and Prevention; Principal Investigator: Ruihua Dong, Beijing Friendship Hospital; Principal Investigator: Kexin Zhao, Hebei Petro China Center Hospital

Study record dates

Study Major Dates

• Study Start (Actual): July 6, 2022
• Primary Completion (Actual): September 21, 2022
• Study Completion (Actual): September 21, 2022

Study Registration Dates

• First Submitted: May 12, 2022
• First Submitted That Met QC Criteria: May 12, 2022
• First Posted (Actual): May 13, 2022

Study Record Updates

• Last Update Posted (Estimated): December 4, 2024
• Last Update Submitted That Met QC Criteria: December 2, 2024
• Last Verified: December 1, 2024

More Information

Terms related to this study

• Keywords: Safety; Vaccine; Immunogenicity; COVID; mRNA; Placebo
• Additional Relevant MeSH Terms: Respiratory Tract Infections; Infections; RNA Virus Infections; Virus Diseases; Respiratory Tract Diseases; Lung Diseases; Pneumonia, Viral; Pneumonia; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; COVID-19
• Other Study ID Numbers: CTP-NCVM-002

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No